CLYM · Climb Bio, Inc.
$17.28
+0.26 (+1.53%)
At close · Aug 21
Market Cap
$992.50M
Shares
57.44M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$59.85M
+19%
FY2025
Diluted EPS
-$0.88
+42.5%
FY2025
Operating Cash Flow
-$54.36M
-249.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $41.9M | $46.71M | $14.34M | $15.41M | $26.21M | $23.32M | $8.77M | |
| $22.86M | $21.17M | $16.03M | $24.86M | $18.92M | $12.35M | $2.43M | |
| — | $97K | $0 | — | — | — | — | |
| $64.76M | $67.88M | $82.02M | $40.28M | $45.14M | $35.67M | $20.93M | |
| -$64.76M | -$67.88M | -$82.02M | -$40.28M | -$45.14M | -$35.67M | -$20.93M | |
| $7.23M | $8.32M | $8.13M | — | — | — | — | |
| $7.13M | $8.03M | $8.12M | $5.16M | -$109K | -$11.81M | $257K | |
| — | $0 | $0 | $0 | $0 | $0 | $0 | |
| -$57.62M | -$59.85M | -$73.9M | -$35.12M | -$45.24M | -$47.48M | -$20.67M | |
| — | — | — | — | -$45.24M | -$52.03M | -$22.95M | |
| -$58.01M | -$59.44M | -$73.87M | -$34.76M | -$45.48M | -$47.6M | — | |
| USD/shares | — | -$0.88 | -$1.53 | -$1.30 | -$1.72 | -$4.24 | — |
| USD/shares | — | -$0.88 | -$1.53 | -$1.30 | -$1.72 | -$4.24 | — |
| shares | — | 67.81M | 48.16M | 26.99M | 26.31M | 12.26M | 2.19M |
| shares | — | 67.81M | 48.16M | 26.99M | 26.31M | 12.26M | 2.19M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 6.74×
EV/EBIT
—
Peer median 21.09×
P/E (TTM)
—
Peer median 14.06×
Peer medians compare against the 296 similar-size Biotechnology companies (of 545 listed).
Key facts
CIK
1768446
CUSIP
28658R106
13F (30d)
106 filings
106 filers
Visit website
Investor relations